ArticleInvestigative ophthalmology & visual science2013
Retinal angiogenesis in the Ins2(Akita) mouse model of diabetic retinopathy.
Article in Investigative ophthalmology & visual science, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 89 citations in OpenAlex.
- Crop-OCT: a Fully Integrated Imageomics Pipeline to Identify Regional and Focal Retinopathy in Murine Models.bioRxiv : the preprint server for biology · 2026Article
- One year of hyperglycemia in the Ins2Akita mouse does not impart changes in retinal vascular patterning.PloS one · 2026Article
- N-acetyl-l-cysteine ethyl ester (NACET) induces the transcription factor NRF2 and prevents retinal aging and diabetic retinopathy.Redox biology · 2025Article
- Diabetic Retinopathy, a Comprehensive Overview on Pathophysiology and Relevant Experimental Models.International journal of molecular sciences · 2025Review
- Novel Therapeutic Approaches for Treatment of Diabetic Retinopathy and Age-Related Macular Degeneration.Vision (Basel, Switzerland) · 2025Review
- Secretogranin III: a promising therapeutic target for intraocular neovascular lesions.International ophthalmology · 2025Review
- Manifestation of Pathology in Animal Models of Diabetic Retinopathy Is Delayed from the Onset of Diabetes.International journal of molecular sciences · 2024Review
- Retinal and metabolic changes in a high-fat diet (HFD)+STZ model of Type II diabetes.Molecular vision · 2024Article
- Diabetic retinopathy: a comprehensive update on in vivo, in vitro and ex vivo experimental models.BMC ophthalmology · 2023Review
- Review
- Diabetes has no additional impact on retinal ganglion cell loss in a mouse model of spontaneous glaucoma.European journal of ophthalmology · 2023Article
- Blockade of Annexin A2 Prevents Early Microvasculopathy in Murine Models of Diabetic Retinopathy.Investigative ophthalmology & visual science · 2023Article
- Rodent Models of Diabetic Retinopathy as a Useful Research Tool to Study Neurovascular Cross-Talk.Biology · 2023Review
- Fluorescence Angiography with Dual Fluorescence for the Early Detection and Longitudinal Quantitation of Vascular Leakage in Retinopathy.Biomedicines · 2023Article
- Systemic Administration of Pegylated Arginase-1 Attenuates the Progression of Diabetic Retinopathy.Cells · 2022Article
- Diabetic Retinopathy: From Animal Models to Cellular Signaling.International journal of molecular sciences · 2022Review
- Investigation of Retinal Metabolic Function in Type 1 Diabetic Akita Mice.Frontiers in cardiovascular medicine · 2022Article
- Polyphenol Metabolite Pyrogallol-International journal of molecular sciences · 2021Article
- Animal models of diabetic retinopathy.Annals of translational medicine · 2021Review
- Gain-of-Function Lrp5 Mutation Improves Bone Mass and Strength and Delays Hyperglycemia in a Mouse Model of Insulin-Deficient Diabetes.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
purposeDiabetic retinopathy (DR) is the leading cause of blindness among working age adults and does not have any curative treatments. Although chemical- and injury-induced models of retinal neovascularization exist, the need for a genetic model that closely simulates the DR pathologic process is great.
methodsHere we characterize the development of the retinal disease phenotype in a genetic model of type 1 diabetes, the Ins2(Akita) mouse, using structural, biochemical, molecular biological, and functional techniques.
resultsThis model exhibits hyperglycemia by 2 months of age and by 6 months we detect retinal complications in Ins2(Akita) males, including early signs of vascular damage consistent with DR, specifically the appearance of pericyte ghosts, vascular leakage, and microaneurysm formation. By 9 months of age, these changes are accompanied by later vascular signs of DR, specifically retinal neovascularization, formation of new capillary beds, and the presence of new blood vessels abnormally localized in the outer plexiform layer. Consistent with the debilitating effects of such vasculopathy, we also observe increased retinal apoptosis and decreased retinal function measured by electroretinogram.
conclusionsThese data indicate that the Ins2(Akita) mouse is a good model for later-onset DR, modeling both early and some late disease signs. Furthermore, this work suggests that this model may be suitable for testing and development of targeted DR therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.